What's Happening

You are here

In this issue, the HSA editorial team brings you safety updates on the use of montelukast and pirfenidone, sibutramine-induced AE characteristics due to adulterated health products, the voluntary withdrawal of Esmya TM Tablet 5mg in Singapore and a case study of Miller Fisher Syndrome in a patient. We would also like to remind healthcare professionals on vaccine AE reporting and to verify HLA-B*1502 status in new patients of Asian ancestry before starting carbamazepine.

We will like to share with you the following article by HSA:
(Click the title of the article below to read more)

The news bulletin is posted on the MOH Health Professional Portal and HSA’s website.

  1. HSA Adverse Drug Reaction News (Dec 2020 Vol.22 No.3)